Published Journal Articles |
||||
 |
Recently Published Artices in Peer-Reviewed Journals
Adding human menopausal gonadotropin to antagonist protocols-is there a benefit?
Meredith K. Martin-Johnston, D.O., Angeline N. Beltsos, M.D., H. Edward Grotjan, Ph.D., and Meike L. Uhler, M.D.
Summary: Regardless of age, adding HMG to recombinant FSH was not beneficial in patients using a GnRH antagonist protocol in a large group practice using a single IVF laboratory.
Reproductive Biomedicine Online 2007;15: 161-168.
Comparison of vitrification and conventional cryopreservation of day 5 and day 6 blastocysts during clinical application.
Juergen Liebermann, Ph.D. and Michael J. Tucker, Ph.D.
Summary: Vitrification technique yields the same implantation and pregnancy rate as slow-frozen blastocyst transfers. Slow growing embryos can be cryopreserved on day 6 because they yield a satisfactory survival, implantation, and pregnancy rate.
Fertility and Sterility 2006: 86: 20-26.
Age-matched comparison of recombinant and urinary hCG for final follicular maturation.
Meike L. Uhler, M.D., Angeline N. Beltsos, M.D., H. Edward Grotjan, Ph.D., Kevin J. Lederer, M.D., and Aaron S. Lifchez, M.D.
Summary: Pregnancy (46 versus 45.2%) and clinical pregnancy rates (38.1 versus 36.8%) were similar for recombinant and urinary hCG. Recombinant hCG was as effective as urinary hCG for final follicular maturation in IVF cycles.
Reproductive Biomedicine Online 2006;13: 315-320.
Vitrification: A successful techniques for cryopreserving human cells in ART.
Juergen Liebermann, Ph.D. and Michael J. Tucker, Ph.D.
Summary: The benefits and potential problems associated with vitrification as a method of choice for embryo cryopresevation in clinical embryology are discussed. Based on the available data, it is clear that vitrification procedures have become increasingly successful and may be a better method than slow cooling for embryo freezing.
Alpha Scientists in Reproductive Medicine; 2005; 32: 4-9.
|
|
||